Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Biologics
  4.  » 
  5. Drug Substance
  6.  » 
  7. Bioconjugate Development
  8.  » Clinical-stage Technology

Antibody-drug Conjugates & Bioconjugates

CLINICAL-STAGE TECHNOLOGY

TRPH-222, a SMARTag anti-CD22 ADC, is in a Phase 1 trial for relapsed/refractory B-cell non-Hodgkin’s lymphoma. In a heavily-pretreated population, the drug induced 6 complete responses and 2 partial responses in the first 22 patients dosed (overall response rate, 36.8%).